Vonoprazan

DRUG INFORMATION

  ADULT
    - Recommended Dosage : Healing of Erosive Esophagitis: 20 mg once daily for 8 weeks.
      Source: US FDA label for vonoprazan (VOQUEZNA), section 'dosage and
      administration', retrieved 2026-08-29
    - ( 2.1 ) Maintenance of Healed Erosive Esophagitis: 10 mg once daily for up to 6
      months.
      Source: US FDA label for vonoprazan (VOQUEZNA), section 'dosage and
      administration', retrieved 2026-08-29
    - ( 2.1 ) Relief of Heartburn Associated with Non-Erosive Gastroesophageal Reflux
      Disease: 10 mg once daily for 4 weeks.
      Source: US FDA label for vonoprazan (VOQUEZNA), section 'dosage and
      administration', retrieved 2026-08-29

  CHILD
    - The safety and effectiveness of VOQUEZNA have not been established in pediatric
      patients.
      Source: US FDA label for vonoprazan (VOQUEZNA), section 'pediatric use', retrieved
      2026-08-29
    - Recommended Dosage : Healing of Erosive Esophagitis: 20 mg once daily for 8 weeks.
      ( 2.1 ) Maintenance of Healed Erosive Esophagitis: 10 mg once daily for up to 6
      months. ( 2.1 ) Relief of Heartburn Associated with Non-Erosive Gastroesophageal
      Reflux Disease: 10 mg once daily for 4 weeks. ( 2.1 ) Treatment of H. pylori
      Infection: see full prescribing information.
      Source: US FDA label for vonoprazan (VOQUEZNA), section 'dosage and
      administration', retrieved 2026-08-29
    - Table 4: Recommended VOQUEZNA Dosage in Patients with Hepatic Impairment:
      Treatment of H. pylori Infection Classification Recommended Dosage Child-Pugh
      Class A 20 mg twice daily Child-Pugh Class B Use is not recommended Child-Pugh
      Class C Use is not recommended 2.4 Administration Instructions Take VOQUEZNA with
      or without food [see Clinical Pharmacology (12.3) ] .
      Source: This line points to a numbered table that this card does not show - read
      that table in the label before you dose. US FDA label for vonoprazan (VOQUEZNA),
      section 'dosage and administration', retrieved 2026-08-29

  RENAL IMPAIRMENT
    - Also refer to the amoxicillin and clarithromycin full prescribing information. 2.2
      Recommended Dosage in Patients with Renal Impairment Healing of Erosive
      Esophagitis The recommended dosage of VOQUEZNA in adult patients with renal
      impairment is described in Table 1 below [see Use in Specific Populations (8.6)
      and Clinical Pharmacology (12.3) ] .
      Source: This line points to a numbered table that this card does not show - read
      that table in the label before you dose. US FDA label for vonoprazan (VOQUEZNA),
      section 'dosage and administration', retrieved 2026-08-29
    - Treatment of H. pylori Infection The recommended dosage of VOQUEZNA in adult
      patients with renal impairment is described in Table 2 below [see Use in Specific
      Populations (8.6) and Clinical Pharmacology (12.3) ].
      Source: This line points to a numbered table that this card does not show - read
      that table in the label before you dose. US FDA label for vonoprazan (VOQUEZNA),
      section 'dosage and administration', retrieved 2026-08-29
    - Table 2: Recommended VOQUEZNA Dosage in Patients with Renal Impairment: Treatment
      of H. pylori Infection Also refer to the Dosage and Administration section of the
      amoxicillin and clarithromycin prescribing information for dosage recommendations
      in patients with renal impairment.
      Source: This line points to a numbered table that this card does not show - read
      that table in the label before you dose. US FDA label for vonoprazan (VOQUEZNA),
      section 'dosage and administration', retrieved 2026-08-29

  HEPATIC IMPAIRMENT
    - ( 2.1 ) See also full prescribing information for the recommended dosage by
      indication for patients with renal or hepatic impairment.
      Source: US FDA label for vonoprazan (VOQUEZNA), section 'dosage and
      administration', retrieved 2026-08-29
    - Estimated GFR Recommended Dosage 30 mL/minute or greater 20 mg twice daily Less
      than 30 mL/minute Use is not recommended 2.3 Recommended Dosage in Patients with
      Hepatic Impairment Healing of Erosive Esophagitis The recommended dosage of
      VOQUEZNA in adult patients with hepatic impairment is described in Table 3 below
      [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3) ] .
      Source: This line points to a numbered table that this card does not show - read
      that table in the label before you dose. US FDA label for vonoprazan (VOQUEZNA),
      section 'dosage and administration', retrieved 2026-08-29
    - Treatment of H. pylori Infection The recommended dosage of VOQUEZNA in adult
      patients with hepatic impairment is described in Table 4 below [see Use in
      Specific Populations (8.7) and Clinical Pharmacology (12.3) ].
      Source: This line points to a numbered table that this card does not show - read
      that table in the label before you dose. US FDA label for vonoprazan (VOQUEZNA),
      section 'dosage and administration', retrieved 2026-08-29

  PREGNANCY
    - Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors
      pregnancy outcomes in women exposed to VOQUEZNA during pregnancy.
      Source: US FDA label for vonoprazan (VOQUEZNA), section 'pregnancy', retrieved
      2026-08-29
    - Healthcare providers are encouraged to register patients by calling 1-866-609-1612
      or visiting https://voqueznapregnancyregistry.com/ .
      Source: US FDA label for vonoprazan (VOQUEZNA), section 'pregnancy', retrieved
      2026-08-29
    - Risk Summary There are no adequate and well-controlled studies of vonoprazan in
      pregnant women.
      Source: US FDA label for vonoprazan (VOQUEZNA), section 'pregnancy', retrieved
      2026-08-29

  BREASTFEEDING
    - In a pre- and postnatal development (PPND) study, pups from dams orally
      administered vonoprazan during organogenesis and through lactation exhibited liver
      discoloration, which, in follow-up mechanistic animal studies, was associated with
      necrosis, fibrosis, and hemorrhage at a dose approximately 22-times the MRHD,
      based on AUC comparisons that were likely attributable to exposure during
      lactation [see Use in Specific Populations (8.2) ] .
      Source: US FDA label for vonoprazan (VOQUEZNA), section 'use in specific
      populations', retrieved 2026-08-29
    - In a PPND study, pregnant female rats were orally administered vonoprazan at doses
      of 1, 3, 10, or 100 mg/kg/day (0.01-, 0.18-, 1.1-, 22-times the MRHD based on AUC
      comparison) from GD 6 to lactation day (LD) 21.
      Source: US FDA label for vonoprazan (VOQUEZNA), section 'use in specific
      populations', retrieved 2026-08-29
    - Decreased body weight gain and food consumption were present in dams at the
      highest dose during lactation.
      Source: US FDA label for vonoprazan (VOQUEZNA), section 'use in specific
      populations', retrieved 2026-08-29